MTOR and renal cell carcinoma: In line with previous experiments evaluating inhibitors of mTOR in TFE3-fusion RCC cell lines [26, 31], NVP-BGT226 decreased the cell cycle S-phase, while not significantly inducing apoptosis (Fig. 3B; Supplementary Figure S4B,C).